BioMarin Reports Strong Revenue, Acquires Amicus
BioMarin Pharmaceutical reported fiscal Q4 and full-year 2025 results on February 23, with full-year revenues rising 13% to $3.2 billion and Q4 revenues up 17% year‑over‑year; VOXZOGO revenue grew 26% for the year and 31% in Q4 while enzyme therapies rose 9% and 13%, respectively. On February 25 Bernstein raised its price target to $94 and maintained an Outperform, and BioMarin announced a definitive agreement to acquire Amicus Therapeutics, expected to accelerate and diversify revenues.
Key Points
- 1Report strong growth: Full-year revenues rose 13% to $3.2B; Q4 revenues up 17%.
- 2Showcase product drivers: VOXZOGO grew 26% yearly, enzymes contributed steady 9% growth.
- 3Indicate strategic impact: Acquisition of Amicus expected to accelerate and diversify BioMarin's revenue base.
Scoring Rationale
Moderate company-level financial and M&A news with official results; limited AI/DS relevance reduces portal-wide impact.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems